Change of plasma transforming growth factor-β1 levels in nasopharyngeal carcinoma patients treated with concurrent chemo-radiotherapy

doi:10.1093/jjco/hyi126

機構典藏 > College of Sciences > Graduate Institute & Department of Mathematics > Journal Article > Item 987654321/41264

Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/41264

Title:	Change of plasma transforming growth factor-β1 levels in nasopharyngeal carcinoma patients treated with concurrent chemo-radiotherapy
Authors:	Chen, Hong-wen;張玉坤;Chang, Yue-cune;Lai, Yuen-liang;Chen, Yu-jen;Huang, Ming-jer;Leu, Yi-shing;Fu, Ying-kai;Wang, Ling-wei;Hwang, Jeng-jong
Contributors:	淡江大學數學學系
Keywords:	transforming growth factor-β1 (TGF-β1);nasopharyngeal carcinoma;concurrent chemo-radiotherapy transforming growth factor-β1 (TGF-β1);nasopharyngeal carcinoma;concurrent chemo-radiotherapy
Date:	2005-08-01
Issue Date:	2010-01-28 07:07:54 (UTC+8)
Publisher:	Oxford University Press
Abstract:	Objective: Our aim was to study the correlation between plasma transforming growth factor (TGF)-β1 level and radiation-induced mucositis and dermatitis in nasopharyngeal carcinoma (NPC) patients. Methods: Blood samples obtained from patients treated with concurrent chemo-radiotherapy (CCRT) were divided into two groups according to the pre-treatment plasma TGF-β1 level (≥7.5 ng/ml as group 1 and <7.5 ng/ml as group 2). Enzyme-linked immunosorbent assay (ELISA) was used for the measurement of the TGF-β1 level. Radiation toxicity was evaluated according to Radiation Treatment Oncology Group criteria. Data were analyzed by the generalized estimation equation method. Results: TGF-β1 levels of group 1 patients were decreased significantly (P = 0.002) at the end of the treatment. The rate of decrease was 0.12 ng/ml per fraction (P = 0.02). The average TGF-β1 level in patients who suffered acute radiation morbidity (grade ≥2) was significantly higher (P = 0.0057) than that of those who suffered less (grade <2). Conclusion: A lower pre-treatment plasma TGF-β1 level and the grade of radiation toxicity both appeared to contribute to the elevated plasma TGF-β1 after CCRT.
Relation:	Japanese Journal of Clinical Oncology 35(8), pp. 427-432
DOI:	10.1093/jjco/hyi126
Appears in Collections:	[Graduate Institute & Department of Mathematics] Journal Article

Files in This Item:

File	Size	Format
	0Kb	Unknown	423	View/Open
Change of plasma transforming growth factor-β1 levels in nasopharyngeal carcinoma patients treated with concurrent chemo-radiotherapy.pdf	129Kb	Adobe PDF	1	View/Open
index.html	0Kb	HTML	147	View/Open

Loading...